Dr. Jeffrey Blaine Ulmer (born 1956)
Wikipedia 🌐 NONE
219 research papers : https://www.researchgate.net/scientific-contributions/Jeffrey-B-Ulmer-38698873
ASSOCIATIONS
Dr. Margaret Ann Liu (born 1956) -
( Dr. Margaret Ann Liu (born 1956) said ... " In my career he was one of the few people who actively (and with great wisdom) mentored me. My first hires included [Dr. John James Donnelly III (born 1954)], [Dr. Jeffrey Blaine Ulmer (born 1956)], and John Shiver as project leaders. We demonstrated the mechanism of Merck’s new Haemophilus influenzae b vaccine (showing that the outer membrane protein complex was an adjuvant, not simply a carrier protein, thus providing an explanation for why Merck’s vaccine was immunogenic in infants of a younger age than other conjugate vaccines). We also worked on bifunctional antibody activation of T cells and sought ways, including utilizing a pseudomonas exotoxin fusion protein to access the class I processing pathway. The goal was to activate cytolytic T cells for both prophylactic vaccines against infectious diseases and cancer immunotherapy. " PDF original at [HP00A4][GDrive] )
Dr. John James Donnelly III (born 1954) ( See above )
...
top co-authors : op co-authors (50)
Karolinska Institutet
Protein Sciences Corporation
Novartis
Novartis
Novartis
2011 (October) - World Vaccine Congress
https://www.youtube.com/watch?v=h_qQ2Ti_3es
New technologies / Dr Jeffrey Ulmer - Novartis - World Vaccine Congress
780 viewsOct 21, 2011
Second video ... on discussion panel ...
https://www.youtube.com/watch?v=NAcB4JCeiXk
Opening Panel Discussion - what are pharma and big biotech looking for in 2010/11?
180 viewsOct 22, 2011
2014 (September 24-26) - Jeffrey Ulmer| Novartis Vaccines & Diagnostics| USA | Vaccines 2014 | OMICS International
https://www.youtube.com/watch?v=DAnm_NJKzWs
2015-06-17-youtube-omics-international-jeffrey-ulmer-novartis-vaccines-and-diagnostics-vaccines-sep-2014-omics-1080p.mp4
https://drive.google.com/file/d/1RHf3Ghpk3-fNEgz3jlvC48vCKp14hgfN/view?usp=sharing
239 viewsJun 17, 2015 /
Title: Technologies for new and improved vaccines.
4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia, Spain
Abstract
Vaccines are without a doubt the most successful of mankind’s medical interventions. However, despite more than two centuries of effective use of vaccines, many substantial challenges remain. These include: 1) improvement of existing but suboptimal vaccines (e.g., tuberculosis, influenza), 2) discovery and development of new vaccines against targets to address large unmet medical needs (e.g., HIV, malaria, cancer), and 3) rapidly responding to new pathogens (e.g., newly emerging microbes, bioweapons). Advances in these areas will require the application of new technologies and paradigms in the areas of antigen identification and optimization, novel potent and safe adjuvants, and enhanced vaccine delivery systems.
Biography
Dr. Jeffrey Ulmer received his B.Sc. with honors from the Department of Chemistry at the University of Regina in 1978 and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University in 1985 and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories and Chiron Corporation he conducted seminal studies on DNA vaccines, and novel vaccine adjuvants and delivery systems. He has published over 190 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy and Human Vaccines, and serves on several external advisory boards. He is currently Global Head of External Research at Novartis Vaccines & Diagnostics, responsible for identification and assessment of new opportunities for collaborative research.
2019 (April) - Youtube video (GSK) - "How is synthetic biology revolutionising vaccines?"
https://www.youtube.com/watch?v=LVhnQ1sqTQU
Apr 23, 2019
Self-replicating mRNA (SAM) is a technology that can help to make effective vaccines more quickly. Watch Jeff Ulmer, Head of Preclinical Research and Development, US, explain how SAM could disrupt the way we make vaccines.
2021 (Jan 07) - Youtube video : "Panel: mRNA Process Development and Manufacturing on the Road to the Clinic"
637 viewsJan 7, 2021
Alliance for Regenerative Medicine
https://www.youtube.com/watch?v=aDiHqZubsf0
2021-01-07-youtube-alliance-for-regenerative-medicine-panel-mrna-process-development-720p.mp4
Sponsored by Aldevron
Messenger RNA offers a promising new approach to address emerging pathogens and unmet medical needs. Shorter lead times and greater simplicity in manufacturing enable faster responses that will transform medicine. This panel will discuss the state of the art with an emphasis on CMC, manufacturing, and associated regulatory issues.
Chair: Nate Spangler, Ph.D., Director of Innovation and Strategy, Aldevron
Speakers:
Frank DeRosa, Ph.D., Chief Technology Officer, Translate Bio
Andrew Geall, Ph.D., Chief Scientific Officer, Precision NanoSystems
Caitlyn Harvey, CMC Strategy and Project Management, Myeloid Therapeutics
Jeffrey Ulmer, Ph.D., mRNA Therapy and Vaccine Expert
Prabook (Jan 7, 2022) - "Jeffrey Blaine Ulmer - biochemist researcher"
"Jeffrey Blaine Ulmer, Canadian, American biochemist, researcher. Recipient merit award Society of Chemical Industry, 1978. Member American Society for Cell Biology, International Society for Vaccines, New York Academy of Sciences."
Born March 5, 1956 in Regina, Saskatchewan, Canada
About
Thirty years in vaccines R&D at Merck Research Laboratories, Chiron Corporation, Novartis Vaccines and GSK. Leadership roles and responsibilities included: Platform Technology Leader (DNA, RNA vaccines), Project Leader (Tuberculosis, SARS), Department Head (Immunology & Cell Biology), Site Head for Research, Global Function Head (External Research), Preclinical R&D Head, and Technical R&D Program Head. Over 200 scientific articles published and inventor on 11 patents.
Experience
Freelance
Vaccines R&D ( Dates Employed : Jul 2020 – Present / Employment Duration : 1 yr 7 mos )
GSK
Head, Preclinical R&D US ( Dates Employed : 2015 – Jul 2020 / Employment Duration : 5 yrs / Rockville, MD )
Novartis
Global Head, External Research ( Dates Employed : 2008 – 2015 / Employment Duration : 7 yrs / Cambridge, MA )
Chiron Corporation
Head, Cell Biology & Immunology ( Dates Employed : 1998 – 2008 / Employment Duration : 10 yrs / Emeryville, CA )
Merck Research Labs
Director, DNA Vaccines ( Dates Employed : 1990 – 1998 / Employment Duration : 8 yrs / West Point, PA )
Education
Yale University School of Medicine
Postdoctoral Fellow / Cell Biology / 1985 – 1990
McGill University
Doctor of Philosophy (PhD) / Biochemistry / 1980 – 1985
only mention in newspapers - https://www.newspapers.com/image/178303146/?terms=jeffrey%20B.%20Ulmer&match=1
https://www.emedevents.com/speaker-profile/jeffrey-ulmer
Jeffrey B. Ulmer BSc, PhD
Head | Rockville, Maryland, United States of America
Specialties :
Biochemistry And Molecular Genetics
Speaks about :
Biochemistry And Molecular Genetics, Cell Biology,...More
Spoken at 5 events
Track Meet Message
Biography :
Dr. Jeffrey Ulmer received his B.Sc. with honors from the Department of Chemistry at the University of Regina in 1978 and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University in 1985 and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories and Chiron Corporation, he conducted seminal studies on DNA vaccines, and novel vaccine adjuvants and delivery systems. Ulmer has published over 190 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy and Human Vaccines, and serves on several external advisory boards. He served as Global Head of External Research at Novartis Vaccines and Diagnostics, responsible for identification and assessment of new opportunities for collaborative research, since the GSK and Novartis acquisition, he is now currently the Head, Preclinical R&D US at GSK vaccines.
2022-01-06-whitepages-com-jeffrey-ulmer-img-1.jpg
https://www.whitepages.com/name/Jeffrey-B-Ulmer/Germantown-MD/P79zREnKe9x
